VIVANI MED.INC. NEW O.N. (U5P) - Cash Flow Conversion Efficiency
Based on the latest financial reports, VIVANI MED.INC. NEW O.N. (U5P) has a cash flow conversion efficiency ratio of -0.427x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.72 Million ≈ $-7.86 Million USD) by net assets (€15.73 Million ≈ $18.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
VIVANI MED.INC. NEW O.N. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how VIVANI MED.INC. NEW O.N.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read VIVANI MED.INC. NEW O.N. (U5P) total liabilities for a breakdown of total debt and financial obligations.
VIVANI MED.INC. NEW O.N. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VIVANI MED.INC. NEW O.N. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vera Bradley Inc
NASDAQ:VRA
|
-0.042x |
|
Falcon Metals Ltd
AU:FAL
|
-0.177x |
|
Noble Development Public Company Limited
BK:NOBLE
|
0.052x |
|
Meiwu Technology Co Ltd
NASDAQ:WNW
|
0.115x |
|
RGB International Bhd
KLSE:0037
|
0.068x |
|
BTCS Inc
NASDAQ:BTCS
|
-0.011x |
|
Anfield Energy Inc.
NASDAQ:AEC
|
-0.070x |
|
VirnetX Holding Corp Common Stock
NYSE:VHC
|
-0.089x |
Annual Cash Flow Conversion Efficiency for VIVANI MED.INC. NEW O.N. (2021–2025)
The table below shows the annual cash flow conversion efficiency of VIVANI MED.INC. NEW O.N. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see U5P company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €15.73 Million ≈ $18.39 Million |
€-24.32 Million ≈ $-28.43 Million |
-1.546x | -30.99% |
| 2024-12-31 | €17.61 Million ≈ $20.59 Million |
€-20.79 Million ≈ $-24.30 Million |
-1.180x | -3.40% |
| 2023-12-31 | €20.76 Million ≈ $24.27 Million |
€-23.70 Million ≈ $-27.71 Million |
-1.142x | -169.22% |
| 2022-12-31 | €44.31 Million ≈ $51.80 Million |
€-18.79 Million ≈ $-21.96 Million |
-0.424x | +90.46% |
| 2021-12-31 | €2.46 Million ≈ $2.88 Million |
€-10.95 Million ≈ $-12.80 Million |
-4.443x | -- |
About VIVANI MED.INC. NEW O.N.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the t… Read more